mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells

High activity of the mechanistic target of rapamycin (mTOR) is associated with poor prognosis in pre-B-cell acute lymphoblastic leukemia (B-ALL), suggesting that inhibiting mTOR might be clinically useful. However, emerging data indicate that mTOR inhibitors are most effective when combined with oth...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Beagle, Brandon R., Nguyen, Duc M., Mallya, Sharmila, Tang, Sarah S., Lu, Mengrou, Zeng, Zhihong, Konopleva, Marina, Vo, Thanh-Trang, Fruman, David A.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2014
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4385838/
https://ncbi.nlm.nih.gov/pubmed/25576920
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items